Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it plans to host an Analyst Meeting, open to members of the professional investment community, on September 28, 2012, from 8:00 to 11:00 am in New York City. Members of Sucampo’s management team will present detailed descriptions of the Company’s prostone technology, its pipeline of development candidates and provide commercial updates for its two FDA-approved prostone-based drugs, AMITIZA® and RESCULA®.
A live webcast of the event will be available in the investor section of Sucampo’s website at http://www.media-server.com/m/p/cdorf2mz. An archived version of the webcast will be available on the Company’s website for a limited time after the event. Please log in approximately 15 minutes prior to the start time to ensure a timely connection.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic catalysis by 15-PGDH of eicosanoids and docosanoids, was first identified by Dr. Ueno. He founded Sucampo Pharmaceuticals in 1996 with Dr. Kuno. For more information, please visit www.sucampo.com.Sucampo Forward-Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.